Allara Prescription and Intake Process: What Actually Happens, Step by Step

What Is Allara and Who Is It For?

Allara is a telehealth company built around a single diagnosis: polycystic ovary syndrome. It pairs patients with reproductive endocrinology-trained clinicians, dietitians, and care coordinators to manage PCOS symptoms including irregular cycles, hyperandrogenism, insulin resistance, and infertility. The platform accepts insurance and offers a cash-pay tier.

PCOS affects between 8% and 13% of reproductive-age women worldwide, depending on diagnostic criteria, according to the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS. That guideline, authored by a consortium across Monash University and over 40 international societies, noted that "up to 70% of affected women remain undiagnosed" in primary care settings. Allara's premise is that a condition-specific platform can close that diagnostic gap faster than a generalist PCP rotation. That premise is reasonable. Whether the execution matches is a separate question this article examines through the lens of published evidence and PCOS treatment guidelines [1].

How the Allara Intake Process Works

The intake begins with a structured online questionnaire covering menstrual history, symptom timeline, prior diagnoses, current medications, and metabolic markers like fasting glucose if available. Expect 15 to 25 minutes. The form collects enough to pre-screen for Rotterdam criteria compliance before a clinician reviews the case.

After submission, Allara schedules a synchronous video visit (typically 30 to 45 minutes) with a nurse practitioner or physician specializing in PCOS. During this visit, the provider reviews the intake form, discusses symptoms, and orders labs. Standard panels include total and free testosterone, DHEA-S, 17-hydroxyprogesterone, fasting insulin, fasting glucose, hemoglobin A1c, lipid panel, TSH, and prolactin. These align with the lab recommendations in the Endocrine Society's 2013 clinical practice guideline on PCOS diagnosis, which specifies excluding thyroid dysfunction, non-classic congenital adrenal hyperplasia, and hyperprolactinemia before confirming a PCOS diagnosis [2].

Labs can be completed at a local Quest or Labcorp draw site. Patients with recent labs (within 3 to 6 months) may upload those instead. Once results are reviewed, the clinician finalizes a treatment plan and sends prescriptions to the patient's preferred pharmacy. The entire process from questionnaire to first prescription typically spans 7 to 14 days.

One structural advantage: the intake is designed for PCOS from the start, not retrofitted from a general women's health template. The questionnaire asks about acanthosis nigricans, hirsutism scoring, and cycle-length variability. These are details a general telehealth platform often skips.

What Allara Prescribes for PCOS

Allara's prescribing patterns follow established PCOS guidelines. The most common medications include metformin, spironolactone, combined oral contraceptives (COCs), and letrozole for ovulation induction.

Metformin remains the most prescribed insulin-sensitizing agent in PCOS. A 2024 Cochrane review analyzing 41 trials (N=4,552) found that metformin reduced fasting insulin by a mean of 3.5 μIU/mL versus placebo and improved ovulation rates (OR 2.55, 95% CI 1.81 to 3.59) [3]. Allara typically starts at 500 mg daily and titrates to 1,500 to 2,000 mg based on tolerance and lab response.

Spironolactone targets hyperandrogenism, specifically acne and hirsutism. The 2023 international guideline recommends it as a first-line anti-androgen for PCOS-related hirsutism when COCs alone are insufficient [1]. Doses range from 50 to 200 mg daily. Because spironolactone is teratogenic, Allara providers require concurrent contraception, a safety step that should be non-negotiable in any prescribing context.

Combined oral contraceptives regulate cycles and reduce androgen levels. The American College of Obstetricians and Gynecologists (ACOG) lists COCs as first-line for menstrual irregularity and hyperandrogenism in PCOS patients not seeking pregnancy [4]. Allara commonly prescribes formulations containing drospirenone or norgestimate, both of which have anti-androgenic or neutral androgenic profiles.

Letrozole is prescribed for patients actively trying to conceive. The NEJM-published trial by Legro et al. (2014) (N=750) showed letrozole produced a live birth rate of 27.5% versus 19.1% for clomiphene citrate (P=0.007) in women with PCOS [5]. This trial changed practice guidelines. The 2023 international guideline now recommends letrozole as first-line for ovulation induction over clomiphene [1].

Allara does not prescribe GLP-1 receptor agonists like semaglutide specifically for PCOS, though some patients with concurrent obesity and insulin resistance may be candidates through separate channels. The platform also does not prescribe inositol, classifying it as a supplement rather than a prescription therapy, though it refers patients to it through its dietitian arm.

Clinical Evidence Behind the Telehealth PCOS Model

No published peer-reviewed trial has evaluated Allara's clinical outcomes specifically. This is a gap, not necessarily a failing, since few condition-specific telehealth platforms have published longitudinal outcome data yet.

What the evidence does support is the general telehealth model for chronic disease management. A 2021 systematic review in the Journal of Medical Internet Research found that telehealth interventions for PCOS improved BMI (mean difference −0.3 kg/m²), menstrual regularity, and patient satisfaction compared to standard care, though effect sizes were modest [6]. The authors noted that "structured telehealth programs with dietitian involvement showed the most consistent improvements in metabolic markers."

The 2023 international guideline specifically endorsed telehealth-delivered lifestyle interventions for PCOS, stating that "telehealth and digital health should be considered to improve access to multidisciplinary care" [1]. Allara's model, combining prescribing with dietitian counseling, aligns with this recommendation structurally.

A separate consideration: PCOS management benefits from continuity. A 2019 analysis published in Fertility and Sterility found that patients who saw the same reproductive endocrinologist for three or more consecutive visits had higher medication adherence (78% vs. 61%, P<0.01) and better cycle regularity outcomes [7]. Whether Allara maintains that continuity depends on staffing and scheduling, something prospective patients should ask about directly during intake.

Allara vs. Other PCOS Telehealth Options

Allara competes with general telehealth platforms (Ro, Hers, Done) and PCOS-adjacent services. The comparison matters because prescribing metformin or spironolactone is not the hard part. Ongoing management is.

General telehealth platforms can prescribe the same drugs. A nurse practitioner on Ro can write for metformin 1,500 mg just as readily as an Allara provider. The difference Allara claims is specialization: providers who focus on PCOS daily, bundled dietitian access, and care coordination designed around the Rotterdam criteria workup.

Compared to an in-person reproductive endocrinologist, Allara trades physical exam capability (ovarian ultrasound, direct hirsutism scoring) for convenience and speed. The 2023 international guideline noted that ultrasound is not required for PCOS diagnosis in adults if both hyperandrogenism and oligo-anovulation are present [1]. This means a telehealth-first model can reach an accurate diagnosis in many cases without imaging, though patients with ambiguous presentations may still need in-person evaluation.

Other PCOS-specific digital platforms exist, including Oova (which focuses on ovulation tracking and hormone monitoring) and various functional medicine practices. Allara's differentiator is the insurance-accepting, prescription-writing clinical model rather than a supplement-first or tracking-first approach. For patients who need pharmaceutical management of insulin resistance, hyperandrogenism, or anovulatory infertility, a prescribing platform is the more direct path.

Insurance, Cost, and Coverage

Allara accepts most major commercial insurance plans and processes claims for both the clinician visit and lab work where covered. For patients without qualifying insurance, Allara offers a cash-pay membership. Pricing has historically ranged from $150 to $250 per month for the cash tier, which typically includes the provider visit, dietitian sessions, and care coordination.

Medication costs are separate and filled at the patient's pharmacy, meaning insurance formulary coverage or GoodRx pricing applies independently of Allara's platform fees. Metformin generic runs $4 to $15 per month at most pharmacies. Spironolactone generic ranges from $10 to $30 monthly. COCs vary widely, from $0 under ACA-mandated contraceptive coverage to $50 or more for branded formulations.

The cost question patients should ask is not just "how much does Allara charge" but "how does total cost compare to seeing a reproductive endocrinologist through my insurance?" For patients with in-network RE access, the office visit copay plus lab copay may be lower than Allara's cash membership. For patients in areas with RE wait times exceeding 8 to 12 weeks (common in rural and underserved regions), Allara's 1-to-2-week intake-to-prescription timeline represents a meaningful access advantage. A 2022 study in Obstetrics & Gynecology found the median wait for a new-patient reproductive endocrinology appointment in the U.S. was 42 days, with 25% of patients waiting over 70 days [8].

Is Allara Legit? Evaluating the Clinical Model

The legitimacy question comes down to three factors: are the providers credentialed, do the treatment protocols follow guidelines, and are there red flags?

On credentials, Allara employs nurse practitioners and physicians with training in reproductive endocrinology and women's health. Providers are licensed in the states where they practice. This is standard for telehealth companies and can be verified through state medical board lookup tools.

On protocols, the prescribing patterns described above (metformin for insulin resistance, spironolactone for hyperandrogenism, COCs for cycle regulation, letrozole for ovulation induction) match the 2023 international evidence-based guideline and ACOG's practice bulletin on PCOS [1][4]. There is no indication that Allara prescribes off-guideline therapies or unproven interventions as core treatment.

On red flags: the main concern with any telehealth platform is visit depth. Dr. Andrea Dunaif, Chief of the Division of Endocrinology, Diabetes, and Bone Disease at Mount Sinai, has stated that "PCOS is a diagnosis of exclusion, and shortcuts in the workup lead to misdiagnosis." A 30-minute video visit can be sufficient for straightforward presentations, but complex cases (suspected Cushing syndrome, late-onset CAH, androgen-secreting tumors) require more extensive evaluation. Patients should confirm that Allara's intake includes 17-OHP and DHEA-S testing and that providers will refer out for cases that exceed telehealth scope.

A second concern is the subscription model itself. Monthly memberships create a financial incentive to retain patients. Patients should evaluate whether they are getting ongoing clinical value from continued membership or whether they have reached a stable medication regimen that their PCP can maintain. Transitioning stable PCOS management to a primary care provider is appropriate and cost-effective for many patients after the initial optimization phase.

Limitations and What Allara Cannot Replace

Allara cannot perform pelvic ultrasounds, which remain part of the Rotterdam diagnostic criteria for patients who do not meet both of the other two criteria (hyperandrogenism and oligo-anovulation). Patients who need imaging for ovarian morphology assessment, endometrial thickness monitoring, or follicle tracking during letrozole cycles will need a local imaging center or OB-GYN.

The platform also does not manage PCOS-related surgical interventions (ovarian drilling, bariatric referrals) or advanced fertility treatments (IVF, gonadotropin injections). These require in-person reproductive endocrinology or fertility clinic care.

For patients with PCOS and concurrent type 2 diabetes, the metabolic management may exceed what a PCOS-focused platform handles optimally. The American Diabetes Association's 2024 Standards of Care recommend comprehensive metabolic management including A1c targets, cardiovascular risk reduction, and kidney function monitoring that a PCOS-specific service may not fully coordinate [9]. Patients with A1c values above 7.0% should confirm whether Allara's team manages diabetes longitudinally or defers to an endocrinologist or diabetologist.

The bottom line on Allara's intake process: it is a well-structured, guideline-aligned entry point for PCOS management that works best for patients with clear-cut presentations who need faster access to first-line pharmacotherapy than their local healthcare system provides. Patients with complex or ambiguous presentations should still pursue in-person evaluation with a reproductive endocrinologist, and all patients on stable regimens should periodically reassess whether continued platform membership adds clinical value beyond what their PCP can deliver.